Opinion

Video

The Role of Trastuzumab Deruxtecan in HER2-Mutated NSCLC

Author(s):

Edgardo S. Santos, MD, FACP, FCCPMartin Dietrich, MD, PhD

Experts on HER2-mutated NSCLC discuss the patient populations in which they’d utilize trastuzumab deruxtecan and share their clinical experiences with the therapy.

Related Videos
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Leah Backhus, MD, MPH, FACS, professor, University Medical Line, Cardiothoracic Surgery, co-director, Thoracic Surgery Clinical Research Program, associate program director, Thoracic Track, CT Surgery Residency Training Program, Thelma and Henry Doelger Professor of Cardiovascular Surgery, Stanford Medicine; chief, Thoracic Surgery, VA Palo Alto
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Medical Oncology, director, Center for Thoracic Cancers, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
5 KOLs are featured in this program
5 KOLs are featured in this program
A panel of 4 experts on lung cancer
A panel of 4 experts on lung cancer
A panel of 5 experts on breast cancer
5 KOLs are featured in this peer exchange
Related Content
Lisa Conte
July 23rd 2024

Crofelemer Misses Diarrhea End Point in Patients With Solid Tumors Receiving Targeted Therapy

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Saul Priceman, PhD, of City of Hope
July 15th 2024

City of Hope CAR T-Cell Therapy for Advanced Prostate Cancer Demonstrates Positive Results in Phase 1 Clinical Trial

Matthew Lunning, DO, FACP, associate professor, the Division of Oncology & Hematology, associate vice chair, research, the Department of Internal Medicine, assistant vice chancellor, clinical research, the University of Nebraska Medical Center
March 18th 2024

Lunning and Herrera Highlight Frontline Hodgkin Lymphoma Management Strategies

Suresh S. Ramalingam, MD, FACP, FASCO, of Winship Cancer Institute
July 12th 2024

Key Data Updates From ASCO May Advance the Treatment Landscapes of 3 Lung Cancer Subtypes

Best Practices in Treating Early-Stage NSCLC
July 11th 2024

Best Practices in Treating Early-Stage NSCLC